CAPTIVA - Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular
Atherostenosis
PRECISE - Perfusion imaging to identify posterior circulation candidates for thrombectomy
Remote ischemic conditioning - Early phase clinical study to evaluate the response of selected blood biomarkers
to remote ischemic conditioning. In addition, to evaluate the tolerability and adherence
to the treatment protocol using a dose escalation design.
RBC deformability in acute stroke - Compared to age matched controls, In addition, RBC nitric oxide, RBC NOS3, and
plasma nitrite levels are compared.
SATURN - A multi-center, prospective randomized, phase 3, pragmatic, open-label, and blinded end-point assessment (PROBE)
clinical trial to determine the effects of continuation vs. discontinuation of statins
on the risk of intracerebral hemorrhage (ICH) recurrence in patients with lobar hemorrhage.
ASPIRE - A randomized, double-blinded, phase 3 clinical trial designed to test the efficacy
and safety of apixaban, compared with aspirin, in patients with a recent intracerebral
hemorrhage (ICH) and high-risk non-valvular atrial fibrillation.
Movement and Memory
A Randomized, Double-Blind, Placebo-Controlled Multiple Dose Study to Assess Efficacy,
Safety, Tolerability, and Pharmacokinetics of ABBV-8E12 in Progressive Supranuclear
Palsy
PSP: An Extension Study of ABBV-8E12 in Progressive Supranuclear Palsy
DAYBREAK: A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814
in Mild Alzheimer’s Disease Dementia
CONGA: This study will evaluate the neurological manifestations of COVID-19 infection within
a prospective cohort of 1,000 patients in Georgia and monitor these over a five-year
time period with a focus on cognition, smell and taste testing alongside molecular
genetic, epigenetic, serologic, proteomic, and metabolomic studies.
National Parkinson Foundation Patient Registry
An Open-Label, Phase 3 Study Examining the Long-Term Safety, Tolerability and Efficacy
of APL-130277 in Levodopa Responsive Patients with Parkinson’s Disease Complicated
by Motor Fluctuations (“OFF” Episodes)
A Phase 3, Twelve-week, Multi-Center, Multinational, Randomized, Double-Blind, Double-Dummy,
Parallel Group Study to Determine the Efficacy, Safety, and Tolerability of P2B001
Once Daily Compared to its Individual Components in Subjects With Early Parkinson’s
Disease and to a Calibration Arm of Pramipexole ER
Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy,
Safety, and Tolerability of 36 Weeks of Treatment with NLY01 in Early-stage Parkinson’s
Disease
Rostock International Parkinson’s Disease Study - An international, multicentre, epidemiological observational study
A 16-Week Open-Label Study of the Effects of Treatment With Pimavanserin on Activities
of Daily Living in Subjects With Parkinson’s Disease Psychosis
A Randomized Placebo-controlled Trial of Zoledronic Acid for Prevention of Fractures
in Patients with Parkinson’s Disease (Referral Center)
A PHASE 3, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED, PARALLEL-GROUP, 27-WEEK TRIAL
TO EVALUATE THE EFFICACY, SAFETY, AND TOLERABILITY OF TWO FIXED DOSES OF TAVAPADON
IN EARLY PARKINSON’S DISEASE (TEMPO-1 TRIAL)
MIND: Long-Term Nicotine Treatment of Mild Cognitive Impairment
Myasthenia Gravis
Alexion 306: Ravulizumab is a C5 complement inhibitor and is being studied for safety and efficacy
in ACHR positive Myasthenia Gravis via intravenous (IV) infusions every 8 weeks. Open
Label use (no placebo) of Ravulizumab is offered to study participants after study
completion.
MG0003: Rozanolixizumab is an FCRN inhibitor and is being studied for safety and efficacy
in ACHR or MuSK positive Myasthenia Gravis via weekly subcutaneous injections.Open Label use (no placebo) of Rozanolixizumab is offered to study participants after
study completion.
RAISE: Zilucoplan is a C5 complement inhibitor and is being studied for safety and efficacy
in ACHR positive Myasthenia Gravis via daily subcutaneous injections. Open Label use
(no placebo) of Zilucoplan is offered to study participants after study completion.
Takeda: TAK-079 is a monoclonal antibody directed against CD38 (B cells) and is being studied
to determine safety, tolerability, and efficacy in ACHR or MuSK positive Myasthenia
Gravis via weekly subcutaneous injections.
Alexion 501: This is an observational study hoping to collect data on patients who are currently
taking eculizumab and have ACHR positive Myasthenia Gravis.
Amyotrophic Lateral Sclerosis
Anelixis: AT-1501 is a monoclonal antibody directed against CD40LG (T cells) and is being studied
for safety and tolerability in ALS via bi-weekly (every other week) intravenous infusions
(IV) with no use of placebo throughout the study.
COMBAT: Ibudilast is a neuroprotective agent that is being studied for safety and efficacy
in ALS via oral capsules taken daily.
Apellis: Pegcetacoplan is a C3 complement inhibitor being studied for safety and efficacy in
ALS via subcutaneous infusions twice per week.
CIDP01:Rozanolixizumab is an FCRN inhibitor and is being studied for safety and efficacy
in CIDP via weekly subcutaneous infusions. Open Label use (no placebo) of Rozanolixizumab
is offered to study participants after study completion.
-Lumbar Disk Herniation-
SKK—SI-6603: an intradiscal injection in the lower back that aims to use Condoliase to alleviate
disc pressure and the compression of the nerve root causing back & leg pain.
Spasmodic Dysphonia
Firdapse in SD: Amifampridine is used to increase the amount of acetylcholine in muscles and is
being studied to determine whether it is effective in reversing side effects from
SD treatments via oral tablets taken daily for 2 weeks.
Stroke Studies
ARPEGGIO - A Randomized, Placebo-Controlled, Double-Blind, Multicenter Study of the Safety and
Neuroprotective Capacity of Scp776 in Subjects Undergoing Endovascular Thrombectomy
for Acute Ischemic Stroke
CAPTIVA - Comparison of Anti-coagulation and anti-Platelet Therapies for Intracranial Vascular
Atherostenosis
Masters2 - MultiStem® Administration for Stroke Treatment and Enhanced Recovery Study
PRECISE - Perfusion imaging to identify posterior circulation candidates for thrombectomy
RBC deformability in acute stroke - Compared to age matched controls, In addition, RBC nitric oxide, RBC NOS3, and plasma
nitrite levels are compared.
Remote ischemic conditioning - Early phase clinical study to evaluate the response of selected blood biomarkers to
remote ischemic conditioning. In addition, to evaluate the tolerability and adherence
to the treatment protocol using a dose escalation design.
LibreXIa-Stroke - A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate
the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention
after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack